Stagezero Life Sciences (TSE:SZLS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
StageZero Life Sciences has reported a decline in its Q1 2024 revenue to $0.523 million from the previous year’s $0.778 million, but also noted a significant reduction in net loss to $0.386 million from $1.812 million. The company highlighted advancements in partnerships and business development in North America and Europe, with a strategic focus on its proprietary Aristotle multi-cancer screening test and the upcoming launch of the COC Protocol 2.0.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money